Wells Fargo’s Coeptis Therapeutics Warrants COEPW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-100
| Closed | -$1 | – | 7341 |
|
|
2026
Q1 | $1 | Hold |
100
| – | – | ﹤0.01% | 7128 |
|
|
2025
Q4 | $1 | Hold |
100
| – | – | ﹤0.01% | 7051 |
|
|
2025
Q3 | $3 | Hold |
100
| – | – | ﹤0.01% | 6966 |
|
|
2025
Q2 | $3 | Hold |
100
| – | – | ﹤0.01% | 7025 |
|
|
2025
Q1 | $1 | Hold |
100
| – | – | ﹤0.01% | 6985 |
|
|
2024
Q4 | $2 | Sell |
100
-100
| -50% | -$2 | ﹤0.01% | 6972 |
|
|
2024
Q3 | $3 | Buy |
+200
| New | +$4 | ﹤0.01% | 6796 |
|
|
2024
Q1 | – | Sell |
-400
| Closed | -$12 | – | 7527 |
|
|
2023
Q4 | $12 | Buy |
400
+300
| +300% | +$12 | ﹤0.01% | 7340 |
|
|
2023
Q3 | $2 | Sell |
100
-152,254
| -100% | -$6.23K | ﹤0.01% | 7527 |
|
|
2023
Q2 | $10.9K | Hold |
152,354
| – | – | ﹤0.01% | 5890 |
|
|
2023
Q1 | $22.4K | Hold |
152,354
| – | – | ﹤0.01% | 5589 |
|
|
2022
Q4 | $15.2K | Hold |
152,354
| – | – | ﹤0.01% | 5376 |
|
|
2022
Q3 | $5K | Hold |
152,354
| – | – | ﹤0.01% | 5893 |
|
|
2022
Q2 | $6K | Sell |
152,354
-100
| -0.1% | -$8 | ﹤0.01% | 5937 |
|
|
2022
Q1 | $12K | Hold |
152,454
| – | – | ﹤0.01% | 6196 |
|
|
2021
Q4 | $49K | Hold |
152,454
| – | – | ﹤0.01% | 5969 |
|
|
2021
Q3 | $39K | Hold |
152,454
| – | – | ﹤0.01% | 5715 |
|
|
2021
Q2 | $82K | Hold |
152,454
| – | – | ﹤0.01% | 5372 |
|
|
2021
Q1 | $66K | Buy |
+152,454
| New | +$143K | ﹤0.01% | 5673 |
|
Other funds holding COEPW
Wells Fargo's COEPW Position: Q2 2026 in Review
Wells Fargo sold out of Coeptis Therapeutics Warrants (COEPW) in Q2 2026, closing a stake of 100 shares — an estimated $1 sold.
Wells Fargo first reported a position in COEPW in Q1 2021 and held it in 19 quarters. The position peaked at $82K in Q2 2021. 3 funds tracked by Wall St. Rank hold COEPW as of Q2 2026.
- Wells Fargo reported no remaining Coeptis Therapeutics Warrants position as of Q2 2026 after selling out during the quarter.
- Wells Fargo sold 100 Coeptis Therapeutics Warrants shares in Q2 2026, an estimated $1.
- Wells Fargo first reported a position in Coeptis Therapeutics Warrants in Q1 2021 and held it in 19 quarters.
- Wells Fargo's Coeptis Therapeutics Warrants position peaked at $82K in Q2 2021.
- 3 funds tracked by Wall St. Rank held Coeptis Therapeutics Warrants as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.